(Q46152812)

20 December 2017

title

A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3. (English)

1 reference

20 December 2017

WSVZUQYMNNHNBK-AGAWFILRSA-N

0 references

1 reference

1 reference

inferred from

reverse claim

corrigendum / erratum

Corrigendum: A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3.

0 references

3

Ryuichi Sawa

1 reference

20 December 2017

author name string

Hideki Hashizume

1

1 reference

20 December 2017

Masayuki Igarashi

2

1 reference

20 December 2017

Hayamitsu Adachi

4

1 reference

20 December 2017

Yoshio Nishimura

5

1 reference

20 December 2017

Yuzuru Akamatsu

6

1 reference

20 December 2017

publication date

1 September 2008

1 reference

20 December 2017

full work available at URL

https://www.nature.com/articles/ja200878.pdf

1 reference

19 March 2024

https://api.unpaywall.org/v2/10.1038/ja.2008.78?email=unpaywall_01@example.com

published in

The Journal of Antibiotics

1 reference

20 December 2017

volume

61

1 reference

20 December 2017

issue

9

1 reference

20 December 2017

page(s)

577-582

1 reference

20 December 2017

https://api.unpaywall.org/v2/10.1038/ja.2008.78?email=unpaywall_01@example.com

1 reference

19 March 2024

access restriction status

open access

1 reference

inferred from online access status

cites work

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

Tripropeptin E, a new tripropeptin group antibiotic produced by Lysobacter sp. BMK333-48F3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

Tripropeptins, novel antimicrobial agents produced by Lysobacter sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

The use of avoparcin as a growth promoter and the occurrence of vancomycin-resistant Enterococcus species in Norwegian poultry and swine production

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

The effect of banning avoparcin on VRE carriage in The Netherlands

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. I. Taxonomy, isolation and biological activities

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

Isolation and characterization of new peptide antibiotics, plusbacins A1-A4 and B1-B4

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.78

7 January 2021

Identifiers

DOI

10.1038/JA.2008.78

1 reference

20 December 2017

1 reference

20 December 2017